Latest Insider Transactions at Point Biopharma Global Inc. (PNT)
This section provides a real-time view of insider transactions for Point Biopharma Global Inc. (PNT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of POINT Biopharma Global Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of POINT Biopharma Global Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Yael Margolin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,710
-100.0%
|
-
|
|
Dec 27
2023
|
David Charles Lubner Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,600
-100.0%
|
-
|
|
Dec 26
2023
|
Jonathan R. Goodman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
41,872
-100.0%
|
-
|
|
Dec 26
2023
|
David Charles Lubner Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
35,400
-90.77%
|
-
|
|
Dec 26
2023
|
Rajesh Malik Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,700
-100.0%
|
-
|
|
Dec 26
2023
|
Gerald L. Hogue Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,596
-100.0%
|
-
|
|
Dec 22
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,494,153
-100.0%
|
-
|
|
Dec 22
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,160
-100.0%
|
-
|
|
Dec 22
2023
|
Allan C Silber Executive Chairman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
8,727,975
-100.0%
|
-
|
|
Dec 22
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
233,529
-100.0%
|
-
|
|
Dec 22
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,773,045
-100.0%
|
-
|
|
Dec 18
2023
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
17,161,278
-100.0%
|
$205,935,336
$12.45 P/Share
|
|
Nov 06
2023
|
Joe A. Mccann Chief Executive Officer |
SELL
Bona fide gift
|
Indirect |
120,000
-3.32%
|
-
|
|
Nov 03
2023
|
Allan C Silber Executive Chairman |
SELL
Bona fide gift
|
Indirect |
500,000
-92.92%
|
-
|
|
Oct 31
2023
|
Neil E. Fleshner Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
250,000
-8.27%
|
-
|
|
Mar 21
2023
|
Gerald L. Hogue Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,936
+45.37%
|
$107,616
$6.97 P/Share
|
|
Nov 29
2022
|
Joe A. Mccann Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,160
+0.06%
|
$12,960
$6.64 P/Share
|
|
Nov 28
2022
|
Rajesh Malik Director |
BUY
Open market or private purchase
|
Direct |
3,700
+50.0%
|
$22,200
$6.66 P/Share
|
|
Nov 25
2022
|
Gerald L. Hogue Director |
BUY
Open market or private purchase
|
Direct |
3,660
+50.0%
|
$21,960
$6.82 P/Share
|
|
Nov 23
2022
|
David Charles Lubner Director |
BUY
Open market or private purchase
|
Direct |
3,600
+50.0%
|
$21,600
$6.85 P/Share
|
|
Nov 21
2022
|
Yael Margolin Director |
BUY
Open market or private purchase
|
Direct |
1,710
+50.0%
|
$10,260
$6.56 P/Share
|
|
Nov 18
2022
|
Allan C Silber Executive Chairman |
BUY
Open market or private purchase
|
Direct |
22,397
+0.52%
|
$134,382
$6.5 P/Share
|
|
Nov 18
2022
|
Jonathan R. Goodman Director |
BUY
Open market or private purchase
|
Indirect |
6,000
+12.53%
|
$36,000
$6.33 P/Share
|
|
Nov 17
2022
|
Allan C Silber Executive Chairman |
BUY
Open market or private purchase
|
Direct |
27,603
+0.65%
|
$165,618
$6.0 P/Share
|
|
May 25
2022
|
Neil E. Fleshner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
564,204
-15.73%
|
$3,949,428
$7.51 P/Share
|
|
Jun 30
2021
|
Neil E. Fleshner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
233,529
+50.0%
|
-
|
|
Jun 30
2021
|
Neil E. Fleshner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,587,249
+50.0%
|
-
|
|
Jun 30
2021
|
Jonathan R. Goodman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
35,872
+50.0%
|
-
|
|
Jun 30
2021
|
Jonathan R. Goodman Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,523
+50.0%
|
-
|
|
Jun 30
2021
|
Michael M. Gottlieb Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,156,887
+50.0%
|
-
|
|
Jun 30
2021
|
Joe A. Mccann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,614,153
+50.0%
|
-
|
|
Jun 30
2021
|
Allan C Silber Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
4,645,486
+50.0%
|
-
|
|
Jun 30
2021
|
Allan C Silber Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
4,218,605
+50.0%
|
-
|
|
Jun 29
2021
|
Peter Kolchinsky Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
209,100
+15.99%
|
$2,091,000
$10.0 P/Share
|
|
Jun 29
2021
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
209,100
+15.99%
|
$2,091,000
$10.0 P/Share
|
|
Jun 24
2021
|
Peter Kolchinsky Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
889,218
+50.0%
|
$8,892,180
$10.0 P/Share
|